This report aims to provide a comprehensive presentation of the global market for Direct-acting Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct-acting Antiviral Drugs. This report contains market size and forecasts of Direct-acting Antiviral Drugs in global, including the following market information:
Global Direct-acting Antiviral Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Direct-acting Antiviral Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
NS3/4A Protease Inhibitors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Direct-acting Antiviral Drugs include AbbVie Inc., GSK, Boehringer Ingelheim, Merck, Novartis, Beximco Pharmaceuticals, Roche, Bristol-Myers Squibb Company and Gilead Sciences, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Direct-acting Antiviral Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Direct-acting Antiviral Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Direct-acting Antiviral Drugs Market Segment Percentages, by Type, 2022 (%)
NS3/4A Protease Inhibitors
Nucleoside and Nucleotide NS5B Polymerase Inhibitors
NS5A Inhibitors
Non-Nucleoside NS5B Polymerase Inhibitors
Global Direct-acting Antiviral Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Direct-acting Antiviral Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others
Global Direct-acting Antiviral Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Direct-acting Antiviral Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Direct-acting Antiviral Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Direct-acting Antiviral Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie Inc.
GSK
Boehringer Ingelheim
Merck
Novartis
Beximco Pharmaceuticals
Roche
Bristol-Myers Squibb Company
Gilead Sciences
Janssen (Johnson & Johnson)
Vertex Pharmaceuticals
Natco Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Direct-acting Antiviral Drugs, market overview.
Chapter 2: Global Direct-acting Antiviral Drugs market size in revenue.
Chapter 3: Detailed analysis of Direct-acting Antiviral Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Direct-acting Antiviral Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Direct-acting Antiviral Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Direct-acting Antiviral Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Direct-acting Antiviral Drugs Overall Market Size
2.1 Global Direct-acting Antiviral Drugs Market Size: 2022 VS 2029
2.2 Global Direct-acting Antiviral Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Direct-acting Antiviral Drugs Players in Global Market
3.2 Top Global Direct-acting Antiviral Drugs Companies Ranked by Revenue
3.3 Global Direct-acting Antiviral Drugs Revenue by Companies
3.4 Top 3 and Top 5 Direct-acting Antiviral Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Direct-acting Antiviral Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Direct-acting Antiviral Drugs Players in Global Market
3.6.1 List of Global Tier 1 Direct-acting Antiviral Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Direct-acting Antiviral Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Direct-acting Antiviral Drugs Market Size Markets, 2022 & 2029
4.1.2 NS3/4A Protease Inhibitors
4.1.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
4.1.4 NS5A Inhibitors
4.1.5 Non-Nucleoside NS5B Polymerase Inhibitors
4.2 By Type - Global Direct-acting Antiviral Drugs Revenue & Forecasts
4.2.1 By Type - Global Direct-acting Antiviral Drugs Revenue, 2018-2023
4.2.2 By Type - Global Direct-acting Antiviral Drugs Revenue, 2024-2029
4.2.3 By Type - Global Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Direct-acting Antiviral Drugs Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Ambulatory Surgical Centers
5.1.5 Pharmacies
5.1.6 Others
5.2 By Application - Global Direct-acting Antiviral Drugs Revenue & Forecasts
5.2.1 By Application - Global Direct-acting Antiviral Drugs Revenue, 2018-2023
5.2.2 By Application - Global Direct-acting Antiviral Drugs Revenue, 2024-2029
5.2.3 By Application - Global Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Direct-acting Antiviral Drugs Market Size, 2022 & 2029
6.2 By Region - Global Direct-acting Antiviral Drugs Revenue & Forecasts
6.2.1 By Region - Global Direct-acting Antiviral Drugs Revenue, 2018-2023
6.2.2 By Region - Global Direct-acting Antiviral Drugs Revenue, 2024-2029
6.2.3 By Region - Global Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Direct-acting Antiviral Drugs Revenue, 2018-2029
6.3.2 US Direct-acting Antiviral Drugs Market Size, 2018-2029
6.3.3 Canada Direct-acting Antiviral Drugs Market Size, 2018-2029
6.3.4 Mexico Direct-acting Antiviral Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Direct-acting Antiviral Drugs Revenue, 2018-2029
6.4.2 Germany Direct-acting Antiviral Drugs Market Size, 2018-2029
6.4.3 France Direct-acting Antiviral Drugs Market Size, 2018-2029
6.4.4 U.K. Direct-acting Antiviral Drugs Market Size, 2018-2029
6.4.5 Italy Direct-acting Antiviral Drugs Market Size, 2018-2029
6.4.6 Russia Direct-acting Antiviral Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Direct-acting Antiviral Drugs Market Size, 2018-2029
6.4.8 Benelux Direct-acting Antiviral Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Direct-acting Antiviral Drugs Revenue, 2018-2029
6.5.2 China Direct-acting Antiviral Drugs Market Size, 2018-2029
6.5.3 Japan Direct-acting Antiviral Drugs Market Size, 2018-2029
6.5.4 South Korea Direct-acting Antiviral Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Direct-acting Antiviral Drugs Market Size, 2018-2029
6.5.6 India Direct-acting Antiviral Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Direct-acting Antiviral Drugs Revenue, 2018-2029
6.6.2 Brazil Direct-acting Antiviral Drugs Market Size, 2018-2029
6.6.3 Argentina Direct-acting Antiviral Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Direct-acting Antiviral Drugs Revenue, 2018-2029
6.7.2 Turkey Direct-acting Antiviral Drugs Market Size, 2018-2029
6.7.3 Israel Direct-acting Antiviral Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Direct-acting Antiviral Drugs Market Size, 2018-2029
6.7.5 UAE Direct-acting Antiviral Drugs Market Size, 2018-2029
7 Direct-acting Antiviral Drugs Companies Profiles
7.1 AbbVie Inc.
7.1.1 AbbVie Inc. Company Summary
7.1.2 AbbVie Inc. Business Overview
7.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Major Product Offerings
7.1.4 AbbVie Inc. Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.1.5 AbbVie Inc. Key News & Latest Developments
7.2 GSK
7.2.1 GSK Company Summary
7.2.2 GSK Business Overview
7.2.3 GSK Direct-acting Antiviral Drugs Major Product Offerings
7.2.4 GSK Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.2.5 GSK Key News & Latest Developments
7.3 Boehringer Ingelheim
7.3.1 Boehringer Ingelheim Company Summary
7.3.2 Boehringer Ingelheim Business Overview
7.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Major Product Offerings
7.3.4 Boehringer Ingelheim Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.3.5 Boehringer Ingelheim Key News & Latest Developments
7.4 Merck
7.4.1 Merck Company Summary
7.4.2 Merck Business Overview
7.4.3 Merck Direct-acting Antiviral Drugs Major Product Offerings
7.4.4 Merck Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.4.5 Merck Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Direct-acting Antiviral Drugs Major Product Offerings
7.5.4 Novartis Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.5.5 Novartis Key News & Latest Developments
7.6 Beximco Pharmaceuticals
7.6.1 Beximco Pharmaceuticals Company Summary
7.6.2 Beximco Pharmaceuticals Business Overview
7.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Major Product Offerings
7.6.4 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.6.5 Beximco Pharmaceuticals Key News & Latest Developments
7.7 Roche
7.7.1 Roche Company Summary
7.7.2 Roche Business Overview
7.7.3 Roche Direct-acting Antiviral Drugs Major Product Offerings
7.7.4 Roche Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.7.5 Roche Key News & Latest Developments
7.8 Bristol-Myers Squibb Company
7.8.1 Bristol-Myers Squibb Company Company Summary
7.8.2 Bristol-Myers Squibb Company Business Overview
7.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Major Product Offerings
7.8.4 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.8.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.9 Gilead Sciences
7.9.1 Gilead Sciences Company Summary
7.9.2 Gilead Sciences Business Overview
7.9.3 Gilead Sciences Direct-acting Antiviral Drugs Major Product Offerings
7.9.4 Gilead Sciences Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.9.5 Gilead Sciences Key News & Latest Developments
7.10 Janssen (Johnson & Johnson)
7.10.1 Janssen (Johnson & Johnson) Company Summary
7.10.2 Janssen (Johnson & Johnson) Business Overview
7.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Major Product Offerings
7.10.4 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.10.5 Janssen (Johnson & Johnson) Key News & Latest Developments
7.11 Vertex Pharmaceuticals
7.11.1 Vertex Pharmaceuticals Company Summary
7.11.2 Vertex Pharmaceuticals Business Overview
7.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Major Product Offerings
7.11.4 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.11.5 Vertex Pharmaceuticals Key News & Latest Developments
7.12 Natco Pharma
7.12.1 Natco Pharma Company Summary
7.12.2 Natco Pharma Business Overview
7.12.3 Natco Pharma Direct-acting Antiviral Drugs Major Product Offerings
7.12.4 Natco Pharma Direct-acting Antiviral Drugs Revenue in Global Market (2018-2023)
7.12.5 Natco Pharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Direct-acting Antiviral Drugs Market Opportunities & Trends in Global Market
Table 2. Direct-acting Antiviral Drugs Market Drivers in Global Market
Table 3. Direct-acting Antiviral Drugs Market Restraints in Global Market
Table 4. Key Players of Direct-acting Antiviral Drugs in Global Market
Table 5. Top Direct-acting Antiviral Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Direct-acting Antiviral Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Direct-acting Antiviral Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Direct-acting Antiviral Drugs Product Type
Table 9. List of Global Tier 1 Direct-acting Antiviral Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Direct-acting Antiviral Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Direct-acting Antiviral Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Direct-acting Antiviral Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Direct-acting Antiviral Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Direct-acting Antiviral Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Direct-acting Antiviral Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Direct-acting Antiviral Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2024-2029
Table 30. AbbVie Inc. Company Summary
Table 31. AbbVie Inc. Direct-acting Antiviral Drugs Product Offerings
Table 32. AbbVie Inc. Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. AbbVie Inc. Key News & Latest Developments
Table 34. GSK Company Summary
Table 35. GSK Direct-acting Antiviral Drugs Product Offerings
Table 36. GSK Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. GSK Key News & Latest Developments
Table 38. Boehringer Ingelheim Company Summary
Table 39. Boehringer Ingelheim Direct-acting Antiviral Drugs Product Offerings
Table 40. Boehringer Ingelheim Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Boehringer Ingelheim Key News & Latest Developments
Table 42. Merck Company Summary
Table 43. Merck Direct-acting Antiviral Drugs Product Offerings
Table 44. Merck Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Merck Key News & Latest Developments
Table 46. Novartis Company Summary
Table 47. Novartis Direct-acting Antiviral Drugs Product Offerings
Table 48. Novartis Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Novartis Key News & Latest Developments
Table 50. Beximco Pharmaceuticals Company Summary
Table 51. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product Offerings
Table 52. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Beximco Pharmaceuticals Key News & Latest Developments
Table 54. Roche Company Summary
Table 55. Roche Direct-acting Antiviral Drugs Product Offerings
Table 56. Roche Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. Roche Key News & Latest Developments
Table 58. Bristol-Myers Squibb Company Company Summary
Table 59. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product Offerings
Table 60. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Bristol-Myers Squibb Company Key News & Latest Developments
Table 62. Gilead Sciences Company Summary
Table 63. Gilead Sciences Direct-acting Antiviral Drugs Product Offerings
Table 64. Gilead Sciences Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Gilead Sciences Key News & Latest Developments
Table 66. Janssen (Johnson & Johnson) Company Summary
Table 67. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product Offerings
Table 68. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Janssen (Johnson & Johnson) Key News & Latest Developments
Table 70. Vertex Pharmaceuticals Company Summary
Table 71. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product Offerings
Table 72. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. Vertex Pharmaceuticals Key News & Latest Developments
Table 74. Natco Pharma Company Summary
Table 75. Natco Pharma Direct-acting Antiviral Drugs Product Offerings
Table 76. Natco Pharma Direct-acting Antiviral Drugs Revenue (US$, Mn) & (2018-2023)
Table 77. Natco Pharma Key News & Latest Developments
List of Figures
Figure 1. Direct-acting Antiviral Drugs Segment by Type in 2022
Figure 2. Direct-acting Antiviral Drugs Segment by Application in 2022
Figure 3. Global Direct-acting Antiviral Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Direct-acting Antiviral Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Direct-acting Antiviral Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Direct-acting Antiviral Drugs Revenue in 2022
Figure 8. By Type - Global Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 16. US Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 28. China Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Direct-acting Antiviral Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Direct-acting Antiviral Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. AbbVie Inc. Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. GSK Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Boehringer Ingelheim Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Merck Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Novartis Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Roche Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Gilead Sciences Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Natco Pharma Direct-acting Antiviral Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
